Loading...
•
Sep 30, 2021
Fulgent Q3 2021 Earnings Report
Reported a revenue increase of 124% year-over-year, reaching $227.9 million.
Key Takeaways
Fulgent Genetics reported strong Q3 2021 results with revenue growing 124% year-over-year to $227.9 million. Core revenue increased by 292% year-over-year to $40.1 million. The company raised its full-year revenue guidance to $930 million, reflecting strength in both its core and COVID-19 businesses.
Revenue grew 124% year-over-year to $227.9 million.
Core Revenue grew 292% year-over-year to $40.1 million.
GAAP income was $122.5 million, or $3.93 per share.
Non-GAAP income was $126.3 million, or $4.05 per share.
Revenue by Segment
Forward Guidance
Fulgent Genetics expects Q4 2021 total revenue of approximately $189 million and core revenue of approximately $32 million, representing growth of 166% year-over-year.
Positive Outlook
- Total Revenue of approximately $189 million
- Core Revenue of approximately $32 million, representing growth of 166% year-over-year
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...